Uses of Shinfemax

Shinfemax is an injectable drug used to treat severe urinary tract infections with complications, severe pneumonia with sepsis or severe infections of the skin and skin structures. To ensure the effectiveness of use when using Shinfemax, users need to follow the instructions of their doctors and refer to the following article for more information about the uses of Shinfemax.

1.1. What is Shinfemax? Shinfemax is a 4th generation cephalosporin antibiotic, with registration number VD-17755-12, manufactured by Shinpoong Daewoo Pharmaceutical Co., Ltd. - Korea. Shinfemax medicine includes the main active ingredient, Cefepim (in the form of a mixture of Cefepim hydrochloride and L-Arginine: 1g The drug is prepared in the form of a powder for injection with a concentration of 1 gram. Shinfemax is prescribed by doctors for use in the following cases:
Severe urinary tract infections with complications caused by Escherichia coli, Pseudomonas aeruginosa or Klebsiella pneumonia Uncomplicated urinary tract infections caused by Escherichia coli, Proteus mirabilis, Klebsiella and Enterobacter Community and hospital-acquired pneumonia caused by Staphylococcus aureus (mr methicillin-susceptible strain), Pseudomonas aeruginosa, Klebsiella (including Klebsiella pneumoniae), Enterobacter, Escherichia coli, Proteus mirabilis, Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains), including those associated with sepsis. If isolated or suspected, aminoglycosides or fluoroquinolones should be combined. Acute infection of chronic bronchitis and acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains). Severe infections of the skin and skin structures caused by methicillin-susceptible strains of Staphylococcus aureus or by cefepime-susceptible Streptococcus pyogenes. Contraindications:
Contraindicated to use Quinacar 5mg for patients allergic to cephalosporin and L-arginine antibiotics.

2.1. How to use Shinfemax Shinfemax drug Shinfemax drug is used by intramuscular, intravenous or intravenous infusion and performed by medical staff:
Intravenous: Mix 1g of Cefepim with 10ml of solvent for injection such as distilled water for injection. , 0.9% sodium chloride solution, 0.9% sodium chloride solution + 5% glucose solution, Ringer's solution, Ringer's solution + 5% glucose solution, 5% or 10% glucose solution, .. . to have drug concentration after mixing 90mg/ml. Administer intravenously slowly for 3-5 minutes. Intermittent intravenous infusion: Mix Cefepime with 10ml of intravenous fluid. Then, the required dose will be calculated and added to the intravenous fluid. Intramuscular injection: Add 2.4 ml of a suitable solvent (with distilled water for injection, 0.9% sodium chloride solution, 5% glucose solution, 0.5 or 1% lidocaine hydrochloride) into the vial containing 1g of Cefepime to Make a solution with a drug concentration of approximately 280 mg. Patients need to adhere to the correct dosage. Do not stop taking your medicine without your doctor's consent.
2.2. Dosage of the drug Shinfemax Patients over 12 years old (over 40kg): 2g every 12 hours, intravenously for 7-10 days. Children 2 months to 12 years (under 40 kg): 50 mg/kg every 12 hours, intravenously for 7-10 days. Children 1-2 months old: 30mg/kg every 12 hours, intravenously for 7-10 days. In very severe infections, the dose may be given every 8 hours. Renal impairment (creatinine clearance < 30 mL/min): Initial dose similar to that in subjects with normal renal function, maintenance dose based on creatinine clearance: ClCr 10-30 mL/min: 50% of the usual dose in 24 hours; or ClCr < 10 ml/min: 25% of the usual 24 hour dose. Patients on dialysis: After each dialysis, it is necessary to compensate with a dose equivalent to the initial dose. Patients undergoing outpatient peritoneal dialysis: The usual dose should be given every 48 hours rather than every 12 hours. Treatment when missed dose:
Shinfemax medicine is taken by medical staff to limit the missed dose. However, if a missed dose of Shinfemax occurs, inject it as soon as you remember, if it is almost time for the next dose, skip the missed dose and continue taking the new dose. Do not double the dose of Shinfemax under any circumstances. Treatment of overdose:
Shinfemax overdose may occur accidentally, especially in people with impaired renal function. In clinical trials, an overdose of cefepime occurred in a patient with renal impairment (creatinine clearance < 11 ml/min) receiving a dose of 2 g every 24 hours for 7 days. This patient presents with epilepsy, encephalopathy, and neuromuscular excitability. The patient needs to stop the drug immediately and notify the doctor for timely treatment.

Shinfemax can be used for pregnant women, but it is necessary to carefully consider the benefits to the mother and the harm to the fetus before appointing. Small amounts of cefepime are excreted in human milk. There are three possible problems for breastfed infants of mothers receiving cefepime: Changes in the microbiota of the gut, direct effects of antibiotics on the infant, and interference with the assessment of feeding outcomes. Bacterial culture if necessary in case of high fever. It is necessary to monitor breastfed infants whose mothers are taking Shinfemax. Use caution when administering the drug to:
Patients with a history of anaphylactic reactions to penicillins (about 5 to 10% of people allergic to penicillin antibiotics have cross-allergy with cephalosporin antibiotics). In the case of severe infections requiring beta-lactam drugs, cephalosporins can be used as an alternative to penicillin-allergic patients but must be closely monitored and anaphylaxis treatment facilities available. Reduce dose in patients with renal impairment. Cefepime solutions should be visually inspected prior to injection for precipitation. Children under 12 years old.

At therapeutic doses, Shinfemax is well tolerated. However, the process of using Shinfemax, patients may still experience side effects such as:
Common:
Diarrhea, rash and pain at the injection site. Uncommon:
Fever, headache, eosinophilia, positive Coombs test without hemolysis, thrombophlebitis (if intravenous), nausea, vomiting, mycosis, oral candidiasis, urticaria , pruritus, increased liver enzymes (reversible) and paresthesia. Rare:
Anaphylaxis, edema, dizziness, neutropenia, hypotension, vasodilatation, colitis, pseudomembranous colitis, abdominal pain, cramps, confusion, arthralgia, inflammation vagina, blurred vision and tinnitus. If you experience these symptoms, the patient should stop using Shinfemax and notify the doctor for appropriate treatment.

Amikacin in combination with cefepime is less likely to cause nephrotoxicity than gentamicin or tobramycin. Avoid concurrent use of Shinfemax with furosemide because it can cause deafness.

The shelf life of Shinfemax medicine is 24 months from the date of manufacture. Store Shinfemax in a cool, dry place, at a temperature not exceeding 30°C, in the original packaging and protected from light, away from acidic environments. Keep Shinfemax out of reach of children. Above is all information about Shinfemax, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Shinfemax at home treatment because there may be unwanted side effects.